Immunomodulation and Patients` Outcomes Following Treatment of Hepatocellular Carcinoma by Radiofrequency Ablation, Microwave Ablation, Trans-Arterial Chemoembolization or Radio-embolization

Overview

About this study

The goal of the study is to identify immune responses (immune cell activation and suppression) following local ablation of liver tumors.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Patients 18-100 years of age
Hepatocellular carcinoma diagnosed by biopsy or non-invasive criteria..
Amenable to radiofrequency , microwave ablations or trans-catheter arterial chemoembolization or radioembolization
Able to undergo blood draws
Willing to return to Rochester for 3 month follow-up
Provision of informed consent

Exclusion Criteria:

Age <18 years
Multicentric HCC (beyond size and number allowed for inclusion)
Lymphovascular or adjacent organ spread
Distant metastasis
Unfit for loco-regional ablation for any other reason

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Lewis Roberts, M.B., Ch.B., Ph.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Lewis Roberts, M.B., Ch.B., Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials